Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia

Chimeric antigen receptor (CAR) T-cell technology has seen a rapid development over the last decade mostly due to the potential that these cells may have in treating malignant diseases. It is a generally accepted principle that very few therapeutic compounds deliver a clinical response without treat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Immunol
Autors principals: Tomuleasa, Ciprian, Fuji, Shigeo, Berce, Cristian, Onaciu, Anca, Chira, Sergiu, Petrushev, Bobe, Micu, Wilhelm-Thomas, Moisoiu, Vlad, Osan, Ciprian, Constantinescu, Catalin, Pasca, Sergiu, Jurj, Ancuta, Pop, Laura, Berindan-Neagoe, Ioana, Dima, Delia, Kitano, Shigehisa
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2018
Matèries:
Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5825894/
https://ncbi.nlm.nih.gov/pubmed/29515572
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.00239
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars